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ABSTRACT 
Molecular testing is rapidly becoming integral to the global tuberculosis (TB) control effort. 
Uncommon mechanisms of resistance can escape detection by these platforms and lead to the 
development of Multi-Drug Resistant (MDR) strains. This article is a systematic review of 
published articles that reported isoniazid (INH) resistance-conferring mutations between 
September-2013 and December-2019. The aims were to catalogue mutations associated with 
INH resistance, estimate their global prevalence and co-occurrence, and their utility in molecular 
diagnostics. The genes commonly associated with INH resistance, katG, inhA, fabG1, and the 
intergenic region oxyR’-ahpC were considered in this review.  In total, 52 articles were included 
describing 5,632 INHR clinical isolates from 31 countries. The three most frequently mutated 
loci continue to be katG315 (4,100), inhA-15 (786), and inhA-8 (105). However, the diagnostic 
value of inhA-8 is far lower than previously thought, only appearing in 25 (0.4%) INHR isolates 
that lacked a mutation at the first two loci.  Importantly, of the four katG loci recommended by 
the previous systematic review for diagnostics, only katG315 was observed in our INHR isolates. 
This indicates continued evolution and regional differences in INH resistance. We have 
identified 58 loci (common to both systematic reviews) in three genomic regions as a reliable 
basis for molecular diagnostics. We also catalogue mutations at 49 new loci associated with INH 
resistance. Including all observed mutations provides a cumulative sensitivity of 85.1%. The 
most disconcerting is the remaining 14.9% of isolates that harbor an unknown mechanism of 
resistance, will escape molecular detection, and likely convert to MDR-TB, further complicating 
treatment. Integrating the information cataloged in this and other similar studies into current 
diagnostic tools is essential for combating the emergence of MDR-TB. Exclusion of this 
information will lead to an “unnatural” selection which will result in eradication of the common 
but propagation of the uncommon mechanisms of resistance, leading to ineffective global 
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treatment policy and a need for region-specific regiments. Finally, the observance of many low-
frequency resistance-conferring mutations point to an advantage of platforms that consider 
regions rather than specific loci for detection of resistance. 
INTRODUCTION 
Tuberculosis (TB) is the most prevalent infectious diseases to date, with an estimated ten 
million new cases in 2018. It is also the infectious disease with highest mortality, recently 
surpassing HIV/AIDS. One of the challenges in global TB control is the emergence of drug 
resistance. Globally, the World Health Organization (WHO) estimates a total of 186,772 
Rifampicin (RIF) and Multidrug Resistant (MDR) (resistant to RIF and isoniazid [INH]) TB cases 
in 2018, a number that has been on the rise in spite of declining total global TB cases. Treatment 
success rate for MDR-TB is low (56%, globally), making its accurate diagnosis and prevention, 
when possible, a critical piece of global TB control. Traditionally culture-based methods are used 
to determine resistance. Isolated bacteria (usually from the patient’s sputum) are cultured in 
presence of a drug. If sufficient growth is observed in a preset timespan, the bacteria are diagnosed 
as resistant. Unfortunately, this process can take weeks, a period during which the patient is treated 
with ineffective drugs allowing the resistant case to further spread, and potentially develop 
resistance to additional drugs.  
Drug resistance in Mycobacterium tuberculosis (M. tuberculosis), the causative agent of 
TB, commonly emerges as a result of a point mutation in specific genes. This knowledge has been 
exploited in the development of molecular diagnostics as a rapid alternative to growth-based 
methods. Molecular testing, however, has an important disadvantage in that it can only detect 
resistant mutations that the platform was designed to detect. Bacteria that harbor uncommon 
mechanisms of resistance, will therefore, escape detection. As a result, the sensitivity in detecting 
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resistance can suffer with increased prevalence of uncommon mechanisms of resistance. It is well 
documented that mono isoniazid resistant (INHR) bacteria often harbor such mechanisms, escape 
detection, and develop into MDR-TB.(1, 2) As a result, incorporation of all resistance conferring 
mutations is critical for comprehensive molecular detection. For this reason, we set out to catalog 
all resistance conferring mutations and estimate global prevalence of common (canonical) and 
uncommon mutations that confer INH resistance. In doing so, we used the search criteria used by 
the previous systematic review by Seifert et al. (3), so the two study’s results can be compared and 
temporal changes in prevalence can be estimated. While Seifert et al. surveyed articles published 
between year 2000 and August 2013, this study continued that survey from September 2013 until 
December 2019.   
 Previous studies have shown that mutations in katG, inhA, fanG1, and the oxyR’-
ahpC intergenic region confer INH resistance.(3, 4) katG codes for a catalase-peroxidase that 
activates INH. Mutations in katG, in particular at codon 315, are commonly observed to cause 
resistance to INH. The second most frequently observed mechanism of resistance is through 
mutations in the promoter of the gene inhA, in particular at position -15. (3)(4) This leads to 
overexpression of the gene which results in removal of the drug from the bacterial cell. (3) 
Mutations in the coding region of the inhA gene also have been associated with resistance. (3)(4) 
Mutations in the oxyR’-ahpC intergenic region may help alleviate the fitness cost of the loss of 
KatG activity in many resistant isolates by increasing the expression of ahpC. (4) Finally, a 
synonymous mutation in fabG1, L203L (CTG203CTA), has been shown to cause INH resistance 
through the creation of an alternative promoter for inhA, and hence causing its overexpression. (5, 
6) 
In this review, we catalog the mutations reported as conferring INH resistance in the three 
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genes and the intergenic region between September 2013 and December 2019, report their 
individual frequencies, estimate the sensitivity of a molecular platform in detecting INH resistance, 
solely based on common mutations, as well as based on all mutations reported in this review. We 
finally, compare the results of this review with that of the previous systematic review to see how 
molecular epidemiology of INH resistance has changed in the last five years. 
METHODS 
Literature Search 
A search in PubMed was conducted on all peer-reviewed publications evaluating mutations 
in katG, inhA, and oxyR-ahpC intergenic region in INHR clinical isolates of M.tuberculosis. In 
order to continue the previous systematic review (3) presented by Seifert et. al., I used the same 
search term used by that study: (isoniazid OR inh) AND (resistance OR resistant) AND (mutations 
OR mutation) AND tuberculosis. The search was limited to studies published between September 
2013 and December 2019 in order to avoid the aggregation of strains that were reported by Seifert 
et. al. That study reported articles published through August 2013. (3)  
Study Selection Criteria 
Studies were included if: 1) written in English; 2) presented original data; 3) used clinical 
strains of Mtb; 4) described the phenotypic DST method used as reference standard; 5) at a 
minimum reported frequency of canonical mutations (in katG codon 315 and inhA promoter 
positions -8 and -15); 6) included individual level amino acid mutation data. Mutations in the 
putative regulatory regions or promoter region were included if available. Studies that performed 
DST on solid or liquid media were included, as long as cut-off concentrations were clearly defined. 
A range of genotypic testing platforms were allowed: Whole Genome Sequencing (WGS) (PacBio 
RS), Line Probe Assay (LPA) using GenoType® MTBDRplus (Hain Lifescience, Nehren, 
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Germany), PCR, GeneXpert (Cepheid, Sunnyvale, CA), and proprietary platforms (only if 
confirmatory data from a secondary platform was available).  
The primary goal of this survey was to reassess the prevalence of canonical mutations. As 
such, any report that did not provide detailed co-mutation (e.g. isolates harboring both katG315 
and inhA -15) counts was excluded since this resulted in overestimation of the prevalence of these 
mutations.  
Data accuracy: To assure the accuracy of the data the following step-wise methodology 
was taken:  
1. This process of mutation curation was repeated twice independently: Each manuscript 
was evaluated independently twice, once in February 2020 and a second time in March 
2020.  
2. Discordance resolution: The manuscripts with discordant counts (between the two 
curation rounds) were assessed for a third time to resolve the discordance. 
3. Parity error check: Two methods were used to detect frequency errors: 
a. Per-locus parity: If the sum of the mutations and wild-type observations 
reported for any locus did not add up to the total isolate count reported in the 
text, the article was excluded. 
b. Isolate count parity: If the total number of mutant and WT isolates reported in 
the tables did not add up to the total isolate count reported, the article was 
excluded. Not reporting of co-mutations, is the common cause of this.   
Data Acquisition 
The following data was extracted from articles that met the inclusion criteria: author names, 
publication year, PubMed ID, DOI, title of the paper, total number of resistant isolates (reported 
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and calculated), total number of isolates harboring each mutation/combination, geographic 
location, method of determining DST, and the method for detecting mutations. Each paper was 
examined for individual mutations and combination of mutations in katG, inhA, fabG1, and oxyR-
ahpC intergenic region. Mutations in the same locus but with a different change was reported 
separately. The frequency of multiple mutations harbored by the same isolate (e.g. katG 315 and 
inhA -15) was reported as a combination, distinct from the frequency of each mutation appearing 
as a stand-alone mutation in isolates. 
In this manuscript, we report the locus of each mutation with respect to Mtb H37Rv genome 
(Accession number NC_000962.3).  
Quality Assessment 
For each mutation reported, the reported reference amino acid was compared to the 
published H37Rv sequence (Accession number NC_000962.3). Mutations reported with a 
reference amino acid discordant with that of H37Rv were excluded from our analysis.  
Statistical Analysis 
Per-mutation analysis: The total number of isolates harboring each distinct mutation (or 
combination thereof) was calculated across all included articles and divided by the total number 
of resistant isolates included in all articles to estimate the diagnostic sensitivity of the mutation. 
Per-locus analysis: The total number of resistant isolates that harbored a mutation in each 
distinct locus was calculated across included articles (regardless of regardless of the type change). 
The total at each locus was then divided by the total number of resistant isolates included in all 
articles to estimate the diagnostic sensitivity of the locus. Since the purpose of this analysis is to 
indicate the importance of inclusion of the locus in diagnostics, combination of mutations that 
included the locus were also included in this analysis. 
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Per-region/gene analysis: To estimate the diagnostic significance of a gene (katG, inhA 
including its promoter) or a region (oxyR’-ahpC intergenic region), the total number of resistant 
isolates reported to harbor a mutation in each region was calculated across the included articles 
and divided by total number of resistant isolates. 
RESULTS 
Description of Included Studies 
Our search through PubMed 
Medline using the terms indicated 
resulted in 509 articles published between 
September 1, 2013 and December 31, 
2019. Out of the 509 potential studies, 52 
studies met all inclusion criteria. (1, 7–59) 
A PRISMA flow diagram in Figure 1 
illustrates the breakdown of number of 
articles excluded because of the specified 
criterion.  
In total, 5792 INHR isolates were reported 
by the 52 included articles. Table 1, 
presents the breakdown per region. 
Overall, nine different methods were used 
in the 52 included studies to detect 
mutations. The most prevalent method was 
PCR followed closely by WGS, and  
Figure 1. PRISMA Flow Diagram. Counts for exclusion criteria. Pubmed 
search term: (isoniazid OR inh) AND (resistance OR resistant) AND 
(mutations OR mutation) AND tuberculosis 
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MTBDRplus. The three methods combined for sequencing over 82% of included isolates. We 
separated LPA and PCR platforms with the distinction that PCR is the category of LPA platforms 
designed inhouse (typically in academic settings). Among such studies, we only included those  
that had reported the PCR primers for each of the canonical mutations. Table 2, presents the full 
list of nine methods and the number of isolates they each sequenced. As compared to the previous 
review(3), perhaps the most notable change in sequencing methodology has been the increase in 
use of WGS. The infrequent use of GeneXpert was also surprising. 
Table 2. Number of isolates stratified by the 
genotyping platform. 
Method Count 
PCR 1643 
WGS 1580 
GenoType MTBDRplus 1566 
LPA 422 
GenoTypeCM Mycobacterium Assay 157 
QMAP 144 
TB-BIOCHIP 135 
HRM /PCR 131 
GeneXpert 14 
Mutations in katG, inhA (promoter and gene), and oxyR-ahpC intergenic region were analyzed and 
are reported in the following section.  
Mutations in KatG. Two sets of mutations were excluded from our analysis: synonymous 
mutations that do not cause any change in the protein, and mutations in codon 463 since they 
appear abundantly among INHR as well as INHS isolates. As depicted by Figure 2, 73 (or 9.8%) of 
the 740 amino acids in KatG harbored a mutation in at least one isolate. Additionally, one study 
Table 1. Breakdown of INHR isolate counts per region of the world. Percentages reflect the percentage of each 
count with respect to the total (5792) INHR isolates included in this study.  
 
Africa  
(1074=18.5%) 
Asia  
(4110=71.02%) 
Europe  
(235=4.05%) 
Americas  
(373=6.43%) 
Region South North East West Central South East West South East South North 
Count 415 39 620 141 348 1980 1641 51 8 176 344 29 
Percentage 7.15 0.67 10.68 2.43 6.00 34.11 28.48 0.88 0.14 3.03 5.93 0.50 
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Figure 2. Frequency of mutations in katG observed in INHR clinical isolates.   
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reported a resistant isolate with deletion of the entire katG (32), while a second reported the 
deletion of katG as well as a substitution of C-52T in the oxyR-ahpC intergenic region of a resistant 
strain (52). Deletion of katG has been shown to cause resistance to isoniazid. In total, ignoring 
codon 463, 4,220 (74.93%) resistant isolates harbored a nonsynonymous mutation in katG. While 
mutations were observed across the gene, the range between codons 235-350 could be considered 
a relative hot spot, with 4,356 (75.05%) resistant isolates harboring a mutation in this region. 
Codon 315 in katG of 4,100 resistant isolates harbored a mutation, providing for a diagnostic 
sensitivity of 72.80%. As expected, this was the locus with the highest frequency of mutations. 
Among the varieties of mutations observed in this codon, katG S315T (AGC-ACC) was the most 
common variety and was harbored by 3,673 (or 65.22%) of resistant isolates.  
Mutations in inhA promoter and open reading frame. The promoter region of inhA, was 
mutated in 966 (17.15%) of the resistant isolates. Of these, 471 (8.36%) resistant isolates also had 
a mutation in KatG, while five had two mutations in inhA or its promoter. Mutations in 16 loci 
were reported in inhA or its promoter. Table 1 lists the loci, the number and percentage of resistant 
isolates that harbored a mutation in each position. The most prevailing inhA promoter locus was -
15, with 776 (13.78%) resistant isolates harboring a mutation at this locus. At this locus, the most 
prevalent mutation was inhA C-15T. Among resistant isolates, 454 (8.06%) harbored this mutation.     
Table 1: Locus describes the position of the mutation in the promoter (negative loci) or within (positive loci) inhA 
gene. Positive loci are codon numbers while negative loci are nucleotide positions within the promoter of the gene. 
Locus -94 -34 -17 -16 -15 -10 -9 -8 -6 -3 9 11 71 94 113 231 
Count 1 16 33 14 787 3 1 106 1 6 2 1 1 3 1 3 
% <0.1 0.3 0.6 0.2 13.6 0.1 <0.1 1.8 <0.1 0.1 <0.1 <0.1 <0.1 0.1 <0.1 0.1 
Mutations in oxyR-ahpC intergenic region. Mutations in the 106bp intergenic region 
between the pseudogenes oxyR and the gene ahpC (H37Rv genome positions 2,726,088 to 
2,726,192) are known to be associated with resistance, although Vilcheze et. al. (4) suggested that 
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mutations in this region may not cause resistance but rather compensate (through overexpression 
of ahpC) for loss of peroxidase function caused by katG mutations. Regardless of the role, the 
association of mutations in this region make them viable candidates for molecular diagnostics. 
Importantly, several studies did not report mutations in this region due to the limitations of the 
molecular platform used for detection of mutations (e.g. GeneXpert). As such, the frequencies 
reported for mutations in this region, underrepresent the frequency of such mutations. 
In total, 113 (2.01%) resistant isolates harbored a mutation in this region or in ahpC coding 
region (2 isolates). Of the 113, 31 (27.43%) isolates also harbored a KatG mutation, while 14 
(12.39%) harbored an inhA (promoter or InhA) mutation. Seven (6.19%) of the 113, harbored a 
mutation both in KatG and inhA (promoter or InhA). Importantly, 75 (66.37%) of the 113 resistant 
isolates, did not harbor a mutation in KatG, or inhA (promoter or InhA).     
Figure 3: Mutations in intergenic region between the genes oxyR and ahpC (106bp in H37Rv 
genome positions 2,726,088 to 2,726,192). Negative positions are nucleotide positions relative to 
the start of the gene ahpC on the positive strand while positive positions are codon numbers in the 
gene’s ORF. Blue bards indicate isolates that also harbor KatG mutations, while orange bars 
indicate isolates that also harbor inhA (promoter or gene) mutations. Grey bars indicate isolates 
that harbor no mutations in inhA (promoter or gene) or in KatG.  Seven isolates had a mutation in 
katG and inhA. 
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DISCUSSION 
Molecular diagnostics is rapid, often cheaper, and at times more portable, promising to 
bring rapid testing to bedside and even into the community at a low cost. It does however take 
testing one more step away from clinical outcomes. While phenotyping was designed to be used 
to predict treatment outcome for a given regimen or drug, molecular platforms are often designed 
and tested as a proxy for the lengthier phenotypic testing. As a result, detailed knowledge about 
the performance of molecular testing and its assumptions is essential. 
One of the dangers of molecular diagnostics is that selection that it could impose on to the 
molecular epidemiology of drug resistant TB. A broadscale application of molecular platforms 
that aim to detect only the canonical mutations, increases the risk of lowering the incidence of 
isolates that harbor canonical mutations, since they are readily detected and appropriately treated, 
while those with uncommon mechanisms of resistance will escape detection and further spread. I 
will refer to this effect as the “unnatural” selection for uncommon mechanisms. This is of particular 
importance for isoniazid resistance since its canonical mutations are well defined (e.g. katG315, 
inhA-15, inhA-8) while quite a few other mutations are also known to cause resistance and 
frequently appear without the presence of canonical mutations. Such strains are likely to escape 
detection by molecular testing and further spread.  
This study was designed with two aims in mind: 1) to catalogue mutations associated with 
INH resistance; 2) to assess the prevalence of canonical mutations; 2) estimate their global 
prevalence and co-occurrence and their utility in molecular diagnostics. For aim 1) I include a 
summary of all the mutations reported in 52 included manuscripts. For aim 2, I report all mutations’ 
frequencies and compare these results to that of the previous survey by Seifert et al.(3) who 
reviewed articles published between January 2000 and August 2013. While this comparison is 
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suboptimal, any notable differences provide additional evidence for our hypothesis that frequent 
global and regional reevaluation of sensitivity and specificity of molecular platforms are essential 
to prevention of emergence of MDR-TB. 
Canonical mutations:  As defined for this manuscript, we have considered mutations that 
appear in codon 315 of katG and promoter mutations at -15 and -8 positions for inhA to be 
canonical. All molecular platforms reported in this survey have targeted these positions for 
mutations. The comparison of the prevalence that we observe as compared to those observed by 
Seifert et al.(3) is presented in Table 4. 
Table 4: Frequency of canonical mutations (September 2013 – December 2019) in this study as 
compared to the previous systematic review by Seifert et al.(3) ending in August 2013. 
*Combining frequencies reported for inhA-8 and mabA-8 by Seifert et al.(3). 
Mutation katG 315 inhA -15 inhA -8 
Study This Study Seifert et al. This Study Seifert et al. This Study Seifert et al. 
Frequency 72.8% 66.2% 14.0% 19% 1.9% 2.25%* 
As it can be seen, the frequency of both canonical mutations in the promoter region of inhA 
are notably lower than the previous systematic review while the frequency of katG315 is higher in 
our review. The cumulative frequencies of these mutations are compared in Table 5. Importantly, 
Seifert et. al. reported mutations in mamA and fabG1 separately. Since these two locus tags refer 
to the same gene, frequencies reported for this gene appears lower than it should be. Additionally, 
since fabG1 and inhA belong to the same operon, promoter loci are reported with respect to the 
beginning of the operon which is the beginning of fabG1 coding region. For example, fabG1-8 and 
inhA-8 tags point to the same locus, namely eight positions upstream of fabG1. However, since 
the authors have reported these separately, the frequencies for these loci appear to be lower than 
they should have been. As such, if we combine the frequency reported for inhA-8 (1% in Table 4) 
and mabA-8 (1.25% Supplemental Table 4), the total frequency of this locus would be 2.25%.         
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Table 5: Cumulative frequency of canonical mutations (September 2013 – December 2019) in 
this study as compared to the previous systematic review by Seifert et al.(3) ending in August 
2013. 
Mutation katG 315 + inhA -15 katG 315 + inhA -15 + inhA -8 
Study This Study Seifert et al. This Study Seifert et al. 
Frequency 81.4% 79.9% 81.9% Not reported 
Mutated loci in katG: Seifert et. al. reported observing at least one mutation in 202 katG 
codons. In this study, we report 73 such loci. Of these, 32 loci are new observations as compared 
to the previous systematic review. Forty-one codons were common between the two studies. It is 
a conclusion of this study that the subset of 41 codons shared between the two studies is a more 
reliable basis for molecular diagnostics rather than those that appear at a slightly higher frequency 
in one study. Several reasons could explain this, including the possibility of clonal expansion in 
an outbreak that might artificially inflate the numbers locally at a given time, but carry less 
significance globally or over a longer span of time. A good example is the set of four katG codon 
recommended by Seifort et al. for diagnostics: 309, 311, 315, and 316. These codons were the 
most frequently mutated codons in their study, where a mutation was observed in 36, 27, 4059, 
and 27 INHR isolates respectively. Of this set of four, only one, codon 315, was observed to harbor 
a mutation in this study. The remaining three would not increase the sensitivity of molecular 
diagnostics in our set of 5792 INHR isolates.    
Mutated loci in inhA: In total, Seifert et al.(3) report a mutation in 44 loci in the promoter 
or coding region of inhA, while we report only 16 such loci in our isolates. Of these, mutations in 
10 loci are new observations as compared to the previous systematic review. Only six (five 
promoter and one coding region) loci were common to both studies: -34, -17, -15, -9, -8, and 143. 
As in the case of katG, we recommend these loci for diagnostics.  This is mostly inline with Seifert 
et. al.’s recommendation with the exception that we have replaced the -47 locus with codon 143. 
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An argument could also be made for inclusion of both loci.  
Mutated loci in oxyR’-ahpC: Seifert et. al. reported observing a mutation in 32 loci in this 
intergenic region or in ahpC coding region while we report observing a mutation in 18 loci. Of 
these mutations in seven loci are new observations as compared to the previous systematic review. 
Eleven loci appeared in both studies: -54, -52, -46, -39, -32, -30, -15, -12, -10, -9, and -6. 
Importantly, while aphC coding loci appeared in the two studies, none were common to both.  
In summary, in addition to the 14.1% of isolates that harbor a yet to be detected mechanism 
of resistance, those that carry a known mechanism but one that is not included in current molecular 
diagnostics, are a source of deep concern. With broad implementation of molecular diagnostics, 
the mechanisms of resistance that are included in molecular diagnostics will be identified and 
eradicated while the remaining resistant strain will escape detection and continue infect others. 
This will result in an “unnatural” (man-made) selection that will result in lower regional detection 
rates and increased prevalence of uncommon mechanisms of resistance. To avoid this, systematic 
reviews such as this need to be annually repeated and the information discovered be be routinely 
included in molecular diagnostics.  
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